FDA Approves ViiV Healthcare's Combivir
Combivir contains a combination of lamivudine and zidovudine.
Lamivudine and zidovudine are antiviral medications. They are in a group of human immunodeficiency virus (HIV) medicines called reverse transcriptase inhibitors. This medication helps keep the HIV virus from reproducing in the body.
Combivir is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). This medication is not a cure for HIV or AIDS.
Combivir is the brand name for a pharmaceutical treatment for HIV infection. It is a fixed dose combination of two antiretroviral drugs, lamivudine (also called 3TC, with the brand name Epivir) and zidovudine (also called AZT, with the brand name Retrovir). The combination of the two drugs has a stronger and more sustained effect than using either drug alone, and assists in reducing pill burden and in aiding compliance with the antiretroviral drug therapy.
Both lamivudine and zidovudine are reverse transcriptase inhibitors, which block the action of an enzyme, reverse transcriptase, that the virus requires for reproduction. It reduces the viral load in the body and raises CD4 cell count.
It was approved for use in the United States by the Food and Drug Administration on September 26, 1997, making it the thirteenth approved antiretroviral. It is marketed by GlaxoSmithKline.
Combivir has some rather unpleasant side effects. Users typically report feeling tired and sick.
Combivir is an HIV medication. It is in a category of HIV medicines called nucleoside reverse transcriptase inhibitors (NRTIs). Combivir prevents HIV from altering the genetic material of healthy CD4 cells. This prevents the cells from producing new virus and decreases the amount of virus in the body.
Combivir is marketed by ViiV Healthcare. It was approved by the U.S. Food and Drug Administration (FDA) for use by people living with HIV in 1997.
Combivir is a combination of two drugs: 300mg of Retrovir (zidovudine) and 150mg of Epivir (lamivudine). Combivir should be prescribed by a healthcare provider for patients who need both of these drugs. Both of these drugs can still be purchased individually for use in combination with other HIV drugs.
Combivir must be combined with at least one other HIV drug, usually a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI).